Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer

Ding, Tze-en Grace; Thomson, Findlay; Stratton, Cory; Cumming, Kirsten; Barrie, Colin; MacLennan, Kirsty; Evans, Tamasin; Campbell, Sorcha; Tufail, Aisha; Mackean, Melanie; Phillips, I.; Stares, Mark

doi:10.1016/s0169-5002(21)00301-9

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group have shown that a novel inflammatory score, the Scottish Inflammatory Prognostic Score (SIPS), predicts survival in patients with NSCLC with PDL-1 expression >50% receiving first-line pembrolizumab monotherapy as per its licensing. In those with the highest levels of inflammation (SIPS2, albumin <35 mg/L and neutrophil count >7.5×10 9 /L) median overall survival was 5.1 months, with no patients demonstrating evidence of long term response (13). Conversely, the median survival of the low inflammation group (SIPS0, albumin ≥35 g/L, neutrophils ≤7.5×10 9 /L) was 28.7 months, with 42% continuing treatment at 1 year.…”

Section: Weeks]mentioning

confidence: 98%

Clinical impact of cachexia biomarkers in advanced cancer

Phillips¹,

Stares²

2023

Ann Palliat Med

View full text Add to dashboard Cite

Section: Weeks]mentioning

confidence: 98%

Clinical impact of cachexia biomarkers in advanced cancer

Phillips¹,

Stares²

2023

Ann Palliat Med

View full text Add to dashboard Cite

“…In patients with NSCLC, the mGPS is predictive of survival, response and resistance to treatment, toxicity and quality of life. Levels of systemic inflammation, determined by the Scottish Inflammatory Prognostic Score (SIPS) can prognosticate outcomes and risk of toxicity in specific lung cancer subgroups, both before treatment and at progression [25,26–28 ▪ ]. By combining ECOG-PS and GPS, Dolan et al [29] demonstrated that increasing PS and inflammation have an additive effect, enhancing their individual prognostic value.…”

Section: Predicting Outcomes In Lung Cancermentioning

confidence: 99%

A traffic light approach for treatment and supportive care stratification in lung cancer

Phillips,

Nottelmann,

Stares

2024

Current Opinion in Supportive &Amp; Palliative Care

Self Cite

View full text Add to dashboard Cite

Purpose of review Comprehensive supportive care interventions for patients with lung cancer are being investigated in a range of ways, including: early palliative care, prehabilitation and rehabilitation. We review recent literature on supportive care and propose a traffic light system to individualise comprehensive supportive care. Green for those very likely to receive anti-cancer treatment, red for those very unlikely to receive anti-cancer treatment and orange where the chance of accessing treatment is uncertain. Comprehensive supportive care can be individualised based on the group a particular patient is in. Recent findings Lung cancer outcomes are improving with the availability of increasingly efficacious treatments; however, treatment rates for advanced disease remain low. In this review, we discuss how person-centred outcomes could be improved, how outcomes can be prognosticated and how the ‘host’ can be staged as well as the cancer. Recent data suggests that early comprehensive supportive care improves quality of life, reduces time spent in hospital and may affect survival. Summary Comprehensive supportive care is likely to improve quality of life in patients with advanced lung cancer. Further work is needed to see if it can improve treatment rates and survival.

show abstract

“…Our local experience is that many patients do not have a CRP as part of their initial investigation for lung cancer. SIPS (Scottish Inflammatory Prognostic Score) predicts overall survival in patients with advanced NSCLC treated with firstline anti-PD1 monotherapy (HR 2.86, 95% CI 2.14-3.83 (p < 0.001)) using albumin and neutrophils [34]. Other scores exist including using Neutrophil/lymphocyte ratio, neutrophil count and the lung immune prognostic score (derived neutrophil count (neutrophil -lymphocytes) and LDH) [35][36][37][38][39][40].…”

Section: Inflammatory Biomarkersmentioning

confidence: 99%

Optimising Outcomes in Non Small Cell Lung Cancer: Targeting Cancer Cachexia

Phillips¹,

Stares²,

Allan³

et al. 2022

Front. Biosci. (Landmark Ed)

Self Cite

View full text Add to dashboard Cite

Lung cancer is the commonest malignancy worldwide and the leading cause of cancer death. Half of patients with lung cancer present with advanced disease. The number of systemic therapies including immunotherapy and targeted treatment are rapidly increasing. Despite this, the outcomes for many patients with locally advanced and advanced lung cancer are poor, as many patients are too unwell for treatment. One of the reasons patients with Non-Small Cell Lung Cancer are not fit for treatment is cancer cachexia, which is common (upto 75% of patients) in this group. This metabolic syndrome presents clinically as weight loss (muscle +/-fat), decreased physical function (patients less active) and anorexia on a background of systemic inflammation. Currently there is not an optimal management pathway for these patients, however, there is emerging data that multi-modal intervention including nutritional support, physical training and pharmacological therapy may have a role in treating cachexia. This review discusses assessment and intervention in cancer cachexia.

show abstract

Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer

Cited by 3 publications

References 0 publications

Clinical impact of cachexia biomarkers in advanced cancer

Clinical impact of cachexia biomarkers in advanced cancer

A traffic light approach for treatment and supportive care stratification in lung cancer

Optimising Outcomes in Non Small Cell Lung Cancer: Targeting Cancer Cachexia

Contact Info

Product

Resources

About